Tumors or cancer of the SPLEEN.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
Nucleosides containing arabinose as their sugar moiety.
A general term for various neoplastic diseases of the lymphoid tissue.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
A continuing periodic change in displacement with respect to a fixed reference. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
Diseases caused by factors involved in one's employment.
The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.
Crafts, trades, professions, or other means of earning a living.
The promotion and maintenance of physical and mental health in the work environment.
Place or physical location of work or employment.
For-profit enterprise with relatively few to moderate number of employees and low to moderate volume of sales.
Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.
A continuous cell line of high contact-inhibition established from NIH Swiss mouse embryo cultures. The cells are useful for DNA transfection and transformation studies. (From ATCC [Internet]. Virginia: American Type Culture Collection; c2002 [cited 2002 Sept 26]. Available from http://www.atcc.org/)
A cabinet department in the Executive Branch of the United States Government concerned with administering those agencies and offices having programs pertaining to health and human services.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research with the objective of cancer prevention, early stage identification and elimination. This Institute was established in 1937.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
An operating division of the US Department of Health and Human Services. It is concerned with the overall planning, promoting, and administering of programs pertaining to health and medical research. Until 1995, it was an agency of the United States PUBLIC HEALTH SERVICE.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
A characteristic symptom complex.
A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.
Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
Acquiring information from a patient on past medical conditions and treatments.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Some members contain triterpenoid saponins.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS.
Exclusive legal rights or privileges applied to inventions, plants, etc.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
A ribonuclease activity that is a component of the HIV REVERSE TRANSCRIPTASE. It removes the RNA strand of the RNA-DNA heteroduplex produced by reverse transcription. Once the RNA moiety is removed a double stranded DNA copy of the HIV RNA can be synthesized.
Compounds containing carbon-phosphorus bonds in which the phosphorus component is also bonded to one or more sulfur atoms. Many of these compounds function as CHOLINERGIC AGENTS and as INSECTICIDES.
A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.
RNA molecules which hybridize to complementary sequences in either RNA or DNA altering the function of the latter. Endogenous antisense RNAs function as regulators of gene expression by a variety of mechanisms. Synthetic antisense RNAs are used to effect the functioning of specific genes for investigative or therapeutic purposes.
Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)
Gram-negative, capsulated, gas-producing rods found widely in nature. Both motile and non-motile strains exist. The species is closely related to KLEBSIELLA PNEUMONIAE and is frequently associated with nosocomial infections
An enzyme that catalyzes the transfer of ribose from uridine to orthophosphate, forming uracil and ribose 1-phosphate.
Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.
An enzyme that catalyzes the reaction between a purine nucleoside and orthophosphate to form a free purine plus ribose-5-phosphate. EC 2.4.2.1.
An enzyme that catalyzes the transfer of 2-deoxy-D-ribose from THYMIDINE to orthophosphate, thereby liberating thymidine.
Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES.
A country spanning from central Asia to the Pacific Ocean.
Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

Base pairing of anhydrohexitol nucleosides with 2,6-diaminopurine, 5-methylcytosine and uracil asbase moiety. (1/176)

Hexitol nucleic acids (HNAs) with modified bases (5-methylcytosine, 2,6-diaminopurine or uracil) were synthesized. The introduction of the 5-methylcytosine base demonstrates that N -benzoylated 5-methylcytosyl-hexitol occurs as the imino tautomer. The base pairing systems (G:CMe, U:D, T:D and U:A) obey Watson-Crick rules. Substituting hT for hU, hCMefor hC and hD for hA generally leads to increased duplex stability. In a single case, replacement of hC by hCMedid not result in duplex stabilization. This sequence-specific effect could be explained by the geometry of the model duplex used for carrying out the thermal stability study. Generally, polypurine HNA sequences give more stable duplexes with their RNA complement than polypyrimidine HNA sequences. This observation supports the hypothesis that, besides changes in stacking pattern, the difference in conformational stress between purine and pyrimidine nucleosides may contribute to duplex stability. Introduction of hCMeand hD in HNA sequences further increases the potential of HNA to function as a steric blocking agent.  (+info)

Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells. (2/176)

In an effort to understand biochemical features that are important to the selective antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine [Cl-F( upward arrow)-dAdo], we evaluated the biochemical pharmacology of three structurally similar compounds that have quite different antitumor activities. Cl-F( upward arrow)-dAdo was 50-fold more potent as an inhibitor of CEM cell growth than were either 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine [Cl-F( downward arrow)-dAdo] or 2-chloro-9-(2-deoxy-2, 2-difluoro-beta-D-ribofuranosyl)adenine [Cl-diF( upward arrow downward arrow)-dAdo]. The compounds were similar as substrates of deoxycytidine kinase. Similar amounts of their respective triphosphates accumulated in CEM cells, and the rate of disappearance of these metabolites was also similar. Cl-F( upward arrow)-dAdo was 10- to 30-fold more potent in its ability to inhibit the incorporation of cytidine into deoxycytidine nucleotides than either Cl-F( downward arrow)-dAdo or Cl-diF( upward arrow downward arrow)-dAdo, respectively, which indicated that ribonucleotide reductase was differentially inhibited by these three compounds. Thus, the differences in the cytotoxicity of these agents toward CEM cells were not related to quantitative differences in the phosphorylation of these agents to active forms but can mostly be accounted for by differences in the inhibition of ribonucleotide reductase activity. Furthermore, the inhibition of RNA and protein synthesis by Cl-F( downward arrow)-dAdo and Cl-diF( upward arrow downward arrow)-dAdo at concentrations similar to those required for the inhibition of DNA synthesis can help explain the poor antitumor selectivity of these two agents because all cells require RNA and protein synthesis.  (+info)

Oligonucleotide-peptide conjugates as potential antisense agents. (3/176)

Oligonucleotide-peptide conjugates have several applications, including their potential use as improved antisense agents for interfering with the RNA function within cells. In order to provide robust and generally applicable conjugation chemistry, we developed a novel approach of fragment coupling of pre-synthesized peptides to the 2'-position of a selected nucleotide within an otherwise protected oligonucleotide chain attached to a solid support.  (+info)

Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. (4/176)

The objective of the present study was to investigate the biochemical pharmacology of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)--a fluorinated analogue of cladribine [2-chloro-2'-deoxyadenosine, Leustatin (CdA)] with improved acid and metabolic stability--in human leukemic cell lines and in mononuclear cells isolated from patients with chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). We have also made and characterized two cell lines that are not sensitive to the growth inhibitory and cytotoxic effects of CAFdA. Incubation of cells isolated from the blood of CLL and AML patients with various concentrations of CdA or of CAFdA accumulated CdA and CAFdA nucleotides in a dose-dependent manner. A significantly higher rate of phosphorylation to monophosphates was observed for CAFdA than for CdA in cells from CLL patients (n = 14; P = 0.04). The differences in the phosphorylation were even more pronounced for the respective triphosphates in both CLL (n = 14; P = 0.001) and AML (n = 4; P = 0.04) cells. Retention of CAFdA 5'-triphosphate (CAFdATP) was also longer than that for CdA 5'-triphosphate (CdATP) in cells from leukemic patients. The relative efficacy of CAFdA as a substrate for purified recombinant deoxycytidine kinase (dCK), the key enzyme in the activation of nucleoside analogues, was very high and exceeded that of CdA as well as the natural substrate, deoxycytidine, by a factor of 2 and 8, respectively. The Km for CAFdA with dCK was also lower than that for CdA, as measured in crude extracts from the human acute lymphoblastic leukemia cell line CCRF-CEM and the promyelocytic leukemia cell line HL60. Acquired resistance to CAFdA in HL60 and in CCRF-CEM cell lines was directly correlated to the decreased activity of the nucleoside phosphorylating enzyme, dCK. Resistant cells also showed a considerable degree of cross-resistance to analogues that were activated by dCK. These observations demonstrated that dCK phosphorylates CAFdA more efficiently than CdA. Furthermore, CAFdATP is apparently more stable than CdATP and the mechanisms of resistance to CAFdA are similar to those leading to CdA resistance. These results encourage studies on the clinical effect of CAFdA in lymphoproliferative diseases.  (+info)

Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. (5/176)

9-Beta-D-Arabinosylguanine (ara-G) is a recently introduced and effective treatment for T-cell acute lymphoblastic leukemia, but how ara-G and ara-G triphosphate (ara-GTP) kill cells is not known. We hypothesized that, in cycling T-lymphoblastoid cells, ara-G may act directly by incorporation into DNA, which may lead to apoptosis. Hence, blocking the incorporation of ara-G monophosphate (ara-GMP) into DNA may prevent apoptosis. To test this hypothesis, we performed experiments in a T-lymphoblastic leukemia cell line (CCRF-CEM) after synchronization with a double aphidicolin block. Intracellular accumulation of ara-GTP was neither cell cycle dependent nor affected by aphidicolin (53 +/- 5 microM/h without aphidicolin, 50 +/- 5 microM/h with aphidicolin). Cells at the G1-S boundary accumulated 75 +/- 7 microM ara-GTP with minimal incorporation into DNA (5 +/- 2 pmol ara-GMP/mg DNA) and had little biochemical or morphological evidence of apoptosis. In marked contrast, cells in S phase had significantly more ara-G incorporated into DNA (24 +/- 4 pmol ara-GMP/mg DNA), although the cytosolic concentration of ara-GTP (85 +/- 7 microM) was similar to that in the G1-enriched population. In the S-phase cells, there was a corresponding increase in apoptosis (measured as high molecular weight DNA fragmentation and morphological changes), and the incorporation of ara-GTP into DNA resulted in a >95% inhibition of DNA synthesis. There was a direct linear relationship between the number of cells in S phase and both the total number of ara-GMP molecules in DNA and the inhibition of DNA synthesis. Blocking of ara-GTP incorporation into S-phase DNA abolished biochemical and morphological features of apoptosis, even in the presence of cytotoxic level of intracellular ara-GTP. Taken together, these data demonstrate that the incorporation of ara-GTP into DNA is the critical event that mediates the induction of apoptosis in CCRF-CEM cells.  (+info)

Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. (6/176)

PURPOSE: To characterize the pharmacokinetics of nelarabine (506U78), the water-soluble prodrug of 9-beta-D-arabinofuranosyl guanine (ara-G), and ara-G in pediatric and adult patients with refractory hematologic malignancies. Ara-G is phosphorylated within leukemic cells to form ara-G triphosphate (ara-GTP), which acts to terminate DNA chain elongation, resulting in cell death. PATIENTS AND METHODS: The pharmacokinetics of nelarabine and/or ara-G were evaluated in 71 patients (25 pediatric and 46 adult patients) on the first day of therapy. Blood was collected at specified times for the determination of plasma nelarabine and ara-G concentrations. RESULTS: There were no statistically significant differences in the pharmacokinetics of nelarabine between any of the groups of patients. The harmonic mean half-life (t1/2) of nelarabine in pediatric and adult patients was 14.1 minutes and 16.5 minutes, respectively. The maximum concentrations (C(max)) of ara-G occurred at or near the end of the nelarabine infusion. The C(max) of ara-G ranged from 11.6 micromol/L to 308.7 micromol/L at nelarabine doses of 5 to 75 mg/kg and was linearly related to the nelarabine dose. No statistically significant differences were noted for the pharmacokinetic parameter estimates of ara-G between adult male and female patients. In children versus adults, the dose-normalized C(max), time of the C(max), and the steady-state volume of distribution of ara-G were similar. However, the clearance of ara-G was higher in pediatric patients (0.312 L.h(-1).kg(-1)) as compared with adult patients (0. 213 L.h(-1).kg(-1)) (P <.001). The t1/2 of ara-G was shorter in pediatric patients as compared with adult patients (2.1 hours v 3.0 hours; P <.01). CONCLUSION: Nelarabine is an effective prodrug of ara-G, allowing systemic concentrations of ara-G that result in clinical activity.  (+info)

Differential incorporation of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosylguanine into nuclear and mitochondrial DNA. (7/176)

The anti-leukemic nucleoside analogs 1-beta-D-arabinofuranosylcytosine (araC) and 9-beta-D-arabinofuranosylguanine (araG) are dependent on intracellular phosphorylation for pharmacological activity. AraC is efficiently phosphorylated by deoxycytidine kinase (dCK). Although araG is phosphorylated by dCK in vitro, it is a preferred substrate of mitochondrial deoxyguanosine kinase. We have used autoradiography to show that araC was incorporated into nuclear DNA in Molt-4 and CEM T-lymphoblastoid cells as well as in Chinese hamster ovary cells. In contrast, araG was predominantly incorporated into mitochondrial DNA in the investigated cell lines, without detectable incorporation into nuclear DNA. These data suggest that the molecular targets of araG and araC may differ.  (+info)

Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. (8/176)

Nucleoside kinases from several species are investigated as "suicide genes" for treatment of malignant tumors by combined gene/chemotherapy. We have recently cloned a multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK), and we have shown that the enzyme phosphorylates cytotoxic pyrimidine and purine nucleoside analogs. The broad substrate specificity of the enzyme, as well as its very high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we evaluated Dm-dNK as a suicide gene by constructing a replication-deficient retroviral vector that expresses the enzyme. The human pancreatic adenocarcinoma cell line MIA PaCa-2 and a thymidine kinase-deficient osteosarcoma cell line were transduced with the recombinant virus. We showed that Dm-dNK can be expressed in human cells, that the enzyme retained its enzymatic activity, and that it is localized in the cell nuclei due to a nuclear localization signal in its C-terminal region. The cells expressing Dm-dNK exhibited increased sensitivity to several cytotoxic nucleoside analogs, such as 1-beta-d-arabinofuranosylcytosine, 1-beta-d-arabinofuranosylthymine, (E)-5-(2-bromovinyl)-2'-deoxyuridine, 2-chloro-2'-deoxyadenosine, and 2',2'-difluorodeoxycytidine. These findings suggest that Dm-dNK may be used as a suicide gene in combined gene/chemotherapy of cancer.  (+info)

Australian Medicines Handbook section 14.1.3 Acute lymphocytic leukaemia is the most common childhood malignancy. Although chemotherapy has improved survival, many children have a high risk of relapse. As chemotherapy can be ineffective in relapsed disease there is a need for new therapies. Clofarabine is a purine nucleoside analogue. It has structural similarities to the purine antagonists cladribine and fludarabine. After dilution and slow intravenous infusion, clofarabine is converted intracellularly to a metabolite which inhibits DNA synthesis and induces apoptosis. There is little hepatic metabolism with 50-60% of the dose being excreted unchanged in the urine. The terminal half-life is approximately five hours. The approval of clofarabine is based on a phase II study of 61 people whose acute lymphocytic leukaemia was refractory or had relapsed at least twice. Their ages ranged from 1 to 20 years with a median of 12 years. Clofarabine was infused for five consecutive days every 2-6 weeks ...
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.. There is no recommended standard treatment for relapsed or refractory acute myelogenous leukemia in older patients. Cytarabine is the most commonly used drug to treat these patients. This study will determine if there is benefit by combining clofarabine with cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either placebo in combination with cytarabine or clofarabine in combination with cytarabine. Randomization was stratified by remission status following the first induction regimen (no remission [i.e., CR1 = refractory] or remission ,6 months vs CR1 = remission ≥6 months). CR1 is defined as remission after first pre-study induction regimen. The safety and tolerability of clofarabine in combination with cytarabine ...
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute or refractory lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.. There is no recommended standard treatment for relapsed or refractory acute myelogenous leukemia in older patients. Cytarabine is the most commonly used drug to treat these patients. This study will determine if there is benefit by combining clofarabine with cytarabine. Patients will be randomized to receive up to 3 cycles of treatment with either placebo in combination with cytarabine or clofarabine in combination with cytarabine. Randomization was stratified by remission status following the first induction regimen (no remission [i.e., CR1 = refractory] or remission ,6 months vs CR1 = remission ≥6 months). CR1 is defined as remission after first pre-study induction regimen. The safety and tolerability of clofarabine in combination with cytarabine ...
This trial will investigate the efficacy and tolerability of clofarabine [Clolar; Genzyme Corporation] and cyclophosphamide [Cytoxan, Neosar] in patients with
Define Aragón. Aragón synonyms, Aragón pronunciation, Aragón translation, English dictionary definition of Aragón. A region and former kingdom of northeast Spain. It was united with Castile in 1479 to form the nucleus of modern Spain. Ar′a·go·nese′ adj. & n.
The goal of this clinical research study is to learn if clofarabine given by mouth on a weekly schedule can help to control MDS. The safety of clofarabine given by mouth will also be studied.
Physician reviewed clofarabine patient information - includes clofarabine description, dosage and directions.Print coupons and compare prices.
Sapacitabine cancer drug molecule (nucleoside analogue). Stylized skeletal formula (chemical structure): Atoms are shown as color-coded circles: hydrogen (hidden), carbon (grey), nitrogen (blue), oxygen (red). - Stock Image F018/3177
The goal of this clinical research study is to compare the ability of decitabine given alone versus the combination of sapacitabine and decitabine to control AML. The safety of the drug combination will also be studied.
Cyclacel Pharmaceuticals Announces Initiation Of Phase 1b/2 Clinical Trial Of Sapacitabine With Olaparib In BRCA Mutant Breast Cancer
Abstract. High dose cytarabine (HiDAC) is the most effective single agent for the treatment of acute myeloid leukemia (AML); clofarabine (CLOF) is also an activ
A Moderate Drug Interaction exists between cladribine and clofarabine. View detailed information regarding this drug interaction.
Evoltra infusion contains the active ingredient clofarabine, which is a type of chemotherapy medicine used to treat cancer known as a cytotoxic antimetabolite. Evoltra infusion is used to treat acute lymphoblastic leukaemia (ALL) in children and adolescents.
CLOLAR(TM)- clofarabine door FDA goedgekeurd medicijn voor ALL - Acute lymfatische Leukemie en dan met name voor kinderen 1 - 21 jaar - met recidief van ALL. Recente studiepublicatie toegevoegd. Artikel update 11 juli 2012
HUMAN BODY TOTAL CARE (HBTC) WITH AFR. A treatment protocol By Wilson Aragão The head is the region of the human body where a number of independent functions are performed: breath, smell, taste, chewing, vision, hearing, balance and neuronal integration.(Melvin Moss)¹ …and the balance of all these functions is directly related to the spatial position of the temporomandibular joints - TMJ. (Wilson Aragão).² The HBTC is a treatment protocol wich reaches all parts of the human body, from the head, integrating all encephalic nerves and their functions, like breathing, chewing, swallowing, smell, taste, hearing, balance and vision. For human beings, breathing, both inhaling and exhaling, must be completely performed by nose. When someone breathes through the nose, the air is filtered by the nasal cavities structures, which are surrounded by the turbines where the air has to make turns to reach the nasalpharynx due to the sinusoidal path. Air is also filtered by the cilia, which retain dirt ...
Using a new process, scientists can create new nucleoside analogues months earlier than with the previous method, paving the way for quicker drug discoveries.
Nelarabine (Arranon) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of leukemia and lymphoma
Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction chemotherapy and attained morphologic complete remission (CR) at day 30 were studied. Pretreatment and CR bone marrow were analyzed using targeted capture DNA sequencing. We analyzed the association between mutation clearance (MC) on the basis of variant allele frequency (VAF) at CR (MC2.5: if the VAF of residual mutations was < 2.5%; MC1.0: if the VAF was < 1%; and complete MC [CMC]: if no detectable residual mutations) and event-free survival, overall survival (OS), and cumulative incidence of relapse (CIR). Results MC1.0 and CMC were associated with significantly better OS (2-year OS: 75% v 61% in MC1.0 v non-MC1.0; P = .0465; 2-year OS: 77% v 60% in CMC v non-CMC; P = .0303) and lower CIR (2-year ...
Goya route in Aragón: turistinformation om turist- och kulturrutter i Spanien. Karta, intressanta platser, logi och aktiviteter.
This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. This medicine may cause serious skin reactions. They can happen weeks to months after starting the medicine. Contact your health care provider right away if you notice fevers or flu-like symptoms with a rash. The rash may be red or purple and then turn into blisters or peeling of the skin. Or, you might notice a red rash with swelling of the face, lips or lymph nodes in your neck or under your arms.. You may need blood work done while you are taking this medicine.. In some cases, you may be given additional medicines to help with side effects. Follow all directions for their use.. Call your doctor or health care provider for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug ...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
This Cited by count includes citations to the following articles in Scholar. The ones marked * may be different from the article in the profile ...
Looking for online definition of clofarabine in the Medical Dictionary? clofarabine explanation free. What is clofarabine? Meaning of clofarabine medical term. What does clofarabine mean?
Clofarabine is a purine nucleoside antimetabolite marketed in the US and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. It is not known if it extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Ongoing trials are assessing its efficacy, if any, for managing other cancers. Clolar was Food and Drug Administration (FDA) approved 28 December 2004. (Under accelerated approval regulations requiring further clinical studies.) Tumor lysis syndrome (TLS). Clofarabine quickly kills leukaemia cells in the blood. The body may react to this. Signs include hyperkalemia, hyperuricemia, and hyperphosphatemia. TLS is very serious and can lead to death if it is not treated right away. ...
Treatment guidelines of the U.S. Department of Health and Human Services state that delavirdine is not recommended as a component of antiretroviral regimens for initial treatment of HIV infection, because of inferior efficacy. Data supporting the effectiveness of delavirdine in combination regimens are limited, both for initial therapy and subsequent therapy. In current clinical practice, agents of demonstrated potency are preferred, and delavirdine is rarely used.. In initial therapy, delavirdine in combination with didanosine + zidovudine did not appear to be more effective than the two nucleoside analogues alone.(1) In NNRTI-naive subjects with virologic failure on dual-nucleoside analogue regimens containing lamivudine, switching to delavirdine + indinavir + a new nucleoside analogue provided superior viral load suppression compared with indinavir + a new nucleoside analogue + lamivudine.(2) A study of indinavir-experienced, NNRTI-naive subjects found a short-term benefit (in terms of ...
RATIONALE: Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the gro
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed ac
Contact Mr. Tarun at +91 9891296838 / 9811747774 to buy and know the price of Atriance or nelarabine price in India. Atriance is a solution for infusion. It contains the active substance nelarabine. Atriance is used to treat patients with T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
For the past 50 years, scientists have used humanmade, synthetic and nucleoside analogues to create drug therapies for diseases that involve the cellular division and/or the viral reproduction of infected cells. These diseases include hepatitis, herpes simplex, HIV and cancer.. But, says Britton, That process has been intensive and challenging, limiting and preventing the discovery of new drug therapies.. Now, using the new process, scientists can create new nucleoside analogues months earlier than with the previous method, paving the way for quicker drug discoveries. A paper on this research was published today in the journal Science.. The reduction in time and cost of synthesis will vary, depending on the individual nucleoside analogue, but we have examples where we cut a 20-plus step synthesis, which takes several months to complete at the very least, down to three or four steps, which would only take a week or so, says Britton.. This is clearly a critical factor when it comes to ...
What is Arranon (Nelarabine)? Learn about drug imprint, side effects, uses (treating), dosage, interaction, overdose, and warnings.
Purpose: Overexpression or polymorphisms of ribonucleotide reductase (RR) are described in many solid tumors, and its expression is highly correlated with survival. However, the biologic significance in multiple myeloma (MM) has not yet been elucidated. Here, we identify the role of RR in MM pathogenesis. Experimental Design: Here we studied the potential utility of RRM1 knockdown effect in multitple myeloma in vitro and in vivo. Results: Knockdown of RRM1 (large subunit) triggered significant growth inhibition, associated with apoptotic cells death, in MM cells, regardless of the existence of bone marrow microcnrivonment. To validate the role of RRM1 of xenograft model, tumor growth was significantly reduced in RRM1-knocked-down MM cells versus control MM cells. Gene expression profiling showed that p53 regulated genes were upregulated after RRM1 knockdown. Immunoblot and QRT-PCR validated that p53 pathways were acviated as well. Clofarabine (CLO), a purine nucleoside analog which inhibits both DNA
Patients who have previously received a hematopoietic stem cell transplant (HSCT) are at higher risk for veno-occlusive disease (VOD) of the liver following treatment with clofarabine (40 mg/m2) when used in combination with etoposide (100 mg/m2) and cyclophosphamide (440 mg/m2). Severe hepatotoxic events have been reported in a combination study of clofarabine in pediatric patients with relapsed or refractory acute leukemia. Two cases (2%) of VOD in the mono-therapy studies were considered related to study drug. Monitor for and discontinue Clolar if VOD is suspected ...
The goal of this clinical research study is to find the highest tolerable dose of gemcitabine (out of 6 possible doses) that can be given in combination
El Instituto de Investigaci n en Ciencias Ambientales de Arag n(IUCA) de la Universidad de Zaragoza impulsa nuevas iniciativas de investigaci n de excelencia e internacionalizaci n para el mejor conocimiento y el progreso de todas las Ciencias Ambientales.
Des Moines, IA (PRWEB) February 24, 2010 -- Group legal insurance leader ARAG® has been selected as a 2009 Workplace Learning and Performance Award winner in
El Instituto de Investigaci n en Ciencias Ambientales de Arag n(IUCA) de la Universidad de Zaragoza impulsa nuevas iniciativas de investigaci n de excelencia e internacionalizaci n para el mejor conocimiento y el progreso de todas las Ciencias Ambientales.
Data Availability StatementThe datasets used and/or analyzed during the current study are available from your corresponding author on reasonable request. were prepared and subsequently stained with eosin and hematoxylin or antibodies for immunofluorescence observation of human being corneal stroma-related proteins. Results SP marketed the appearance of corneal stroma-related collagens (collagen types I, III, V, and VI) through the differentiation induced by KDM. Patterned silk membrane led cell position of PDLSCs, and essential ECM the different parts of the corneal stroma had been been shown to be transferred with the cells. The built multi-lamellar tissues was found to aid cells developing between every two levels and expressing the primary kind of collagens (collagen types I and V) and proteoglycans (lumican and keratocan) of Clofarabine price Clofarabine price regular individual corneal stroma. Conclusions Multi-lamellar individual corneal stroma-like tissues could be built in vitro by ...
The chromosome is at the heart of all genetic processes with the programmed expression of its content being central to the development of an organism.
Weather. Hourly data and daily summaries from the network of automatic stations: Arag s del Puerto - Datos horarios - Charts - temperatura
Weather. Hourly data and daily summaries from the network of automatic stations: Arag n - Datos horarios - Map - Temperature (°C)
Sullivan, M. J. P., Talbot, J., Lewis, S. L., Phillips, O. L., Qie, L., Begne, S. K., Chave, J., Cuni-Sanchez, A., Hubau, W., Lopez-Gonzalez, G., Miles, L., Monteagudo-Mendoza, A., Sonké, B., Sunderland, T., ter Steege, H., White, L. J. T., Affum-Baffoe, K., Aiba, S. -ichiro, de Almeida, E. C., de Oliveira, E. A., Alvarez-Loayza, P., Dávila, E. Á., Andrade, A., Aragão, L. E. O. C., Ashton, P., Aymard C., G. A., Baker, T. R., Balinga, M., Banin, L. F., Baraloto, C., Bastin, J. - F., Berry, N., Bogaert, J., Bonal, D., Bongers, F., Brienen, R., Camargo, J. L. C., Cerón, C., Moscoso, V. C., Chezeaux, E., Clark, C. J., Pacheco, Á. C., Comiskey, J. A., Valverde, F. C., Coronado, E. N. H., Dargie, G., Davies, S. J., De Canniere, C., Djuikouo K., M. N., Doucet, J. - L., Erwin, T. L., Espejo, J. S., Ewango, C. E. N., Fauset, S., Feldpausch, T. R., Herrera, R., Gilpin, M., Gloor, E., Hall, J. S., Harris, D. J., Hart, T. B., Kartawinata, K., Kho, L. K., Kitayama, K., Laurance, S. G. W., Laurance, W. ...
Agratech - Sprayer, Spraytip & Nozzle Specialists. Call us on 01706 211399 for Cooper Pegler, Hypro, Matabi, Berthoud, Mesto, Enduramaxx, Arag and much more.
GlaxoSmithKlines Atriance® (nelarabine solution for infusion) has received a positive opinion from the European Medicines Agency (EMEA) for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in patients whose disease has not responded to, or has relapsed following, treatment with at least two chemotherapy regimens.. Atriance® is now being considered for final marketing approval by the European Commission for these difficult to treat forms of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL): T-ALL and T-LBL.. According to Paolo Paoletti, SVP and Global Head of Oncologylinks Research and Development, GSK:. Nelarabine may offer some patients the chance to go on to have potentially curative treatment, such as a stem cell transplant, so we are delighted that nelarabine has been granted a positive opinion from the EMEA.. We are immensely proud of our involvement in the development of this orphan drug for such a rare disease, ...
A purine nucleoside analog and antineoplastic agent used for the treatment of with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma with inadequate clinical response to prior chemotherapeutic treatments.
In previous studies, DNA excision repair initiated by UV or 4-HC in quiescent normal lymphocytes allowed the nucleoside analogue F-ara-A to be incorporated into the repair patch (15 , 40) , an action that was associated with the inhibition of the repair processes. In both, such mechanism-based interactions enhanced cytotoxicity. The present study extended this approach to CLL lymphocytes. Although the magnitude of the repair response was heterogeneous in these primary tumor cells, DNA repair was initiated promptly and completed rapidly in most cases. Treating cells with F-ara-A or Cl-F-ara-A before the addition of 4-HC maximized the repair inhibition with the greatest effect at their intracellular triphosphate concentrations at 50 or 5 μm, respectively. The combinations produced more than additive apoptotic cell death than the sum of each agent alone. This increase in cytotoxicity was proportional to the extent of repair inhibition by these nucleoside analogues or to the initial tail-moment ...
Por favor, lee nuestra Cookies policy para conocer con mayor detalle las cookies que usamos, su finalidad y como poder configurarlas o rechazarlas, si así lo considera ...
Brack, W., Altenburger, R., Schüürmann, G., Krauss, M., López Herráez, D., van Gils, J., Slobodnik, J., Munthe, J., Gawlik, B.M., van Wezel, A., Schriks, M., Hollender, J., Tollefsen, K.E., Mekenyan, O., Dimitrov, S., Bunke, D., Cousins, I., Posthuma, L., van den Brink, P.J., López de Alda, M., Barceló, D., Faust, M., Kortenkamp, A., Scrimshaw, M., Ignatova, S.N., Engelen, G., Massmann, G., Lemkine, G., Teodorovic, I., Walz, K.-H., Dulio, V., Jonker, M.T.O., Jäger, F., Chipman, K., Falciani, F., Liska, I., Rooke, D., Zhang, X., Hollert, H., Vrana, B., Hilscherova, K., Kramer, K., Neumann, S., Hammerbacher, R., Backhaus, T., Mack, J., Segner, H., Escher, B., De Aragão Umbuzeiro, G., (2015 ...
Ernesto Cobos González, José Arturo Aragón López, Danny Rolando Soria Céspedes, Marco Antonio de la Rosa Abaroa, Andrea Martínez de la Vega Celorio, Martín Granados Gracia, Enrique Bargalló Rocha ...
Find information about Clofarabine including usage and side effects. Browse our Drug Dictionary for generic drug names and brand names.
Pentostatin (Nipent) has demonstrated significant activity as a single agent in patients with low-grade B- and T-cell lymphomas, but thus far, clinical experience with combinations of pentostatin and other agents is limited. A study
Deoxyguanosine kinase (ATP: deoxyguanosine 5-phosphotransferase) activity has been identified in neonatal mouse skin tissue. This activity which has a molecular weight of 44 000 was shown to be highly specific for deoxyguanosine as a substrate. Unique to deoxynucleoside kinases was the observation that this enzyme possessed a pH optimum of 5.2. In dilute solutions catalytic activity is lost, however the enzymatic activity can be stabilized by the addition of 20 micrometer MgATP or ATP. Kinetic analysis gave an apparent Km for deoxyguanosine of 7 micrometer. Double-reciprocal plots of activity vs. MgATP concentration produced a broken line with the break occurring at 0.5 mM MgATP. Below this concentration an apparent Km for MgATP of 23 micrometer was measured; above 0.5 mM MgATP an apparent Km of 265 micrometer was calculated. Mouse skin deoxyguanosine kinase was strongly inhibited by dGTP, dGDP and UDp. dGTP was a competitive inhibitor of deoxyguanisine with an apparent Ki of 1.9 micrometer. UPD (K1
This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. This medicine may cause serious skin reactions. They can happen weeks to months after starting the medicine. Contact your health care provider right away if you notice fevers or flu-like symptoms with a rash. The rash may be red or purple and then turn into blisters or peeling of the skin. Or, you might notice a red rash with swelling of the face, lips or lymph nodes in your neck or under your arms.. You may need blood work done while you are taking this medicine.. In some cases, you may be given additional medicines to help with side effects. Follow all directions for their use.. Call your doctor or health care provider for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug ...
This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. This medicine may cause serious skin reactions. They can happen weeks to months after starting the medicine. Contact your health care provider right away if you notice fevers or flu-like symptoms with a rash. The rash may be red or purple and then turn into blisters or peeling of the skin. Or, you might notice a red rash with swelling of the face, lips or lymph nodes in your neck or under your arms.. You may need blood work done while you are taking this medicine.. In some cases, you may be given additional medicines to help with side effects. Follow all directions for their use.. Call your doctor or health care provider for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug ...
Street prednisolone lilly 20mg preisvergleich in zu. Product is fine and arrived quickly, all the way to the UK! «Developing the Purine Nucleoside Analogue Acyclovir: the Work of Gertrude B? These studies have all been completed, generic cialis vs brand cialis reviews but results are pending? Made to be worn over the hoop, enrico prandin commercialista adding graceful fullness and keeping the bones of the hoop skirt from showing through? In sometimes dostinex online uk case of adults with initial episodes of genital herpes, the dosage will be 1 gram to be taken two times daily for about 10 days. Further, cialis usa the fact that a veniremember would hold the State to a higher burden of proof is a race-neutral reason for striking that veniremember! Bei entsprechender Behandlung überleben vier von fünf Patienten diese Komplikation! Now jazzily kytril cost its fall, I take 450mg, by winter Ill be at 600mg! Far the easier but psychological support is equally important for successful outcome. ...
Interventions: Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine; Radiation: Total Body Irradiation (TBI); Drug: Thymoglobulin; Biological: Stem Cell Infusion; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Decitabine; Drug: Cytarabine; Drug: ...
Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18. Related citations ...
Brack, W., Altenburger, R., Schüürmann, G., Krauss, M., López Herráez, D., van Gils, J., Slobodnik, J., Munthe, J., Gawlik, B.M., van Wezel, A., Schriks, M., Hollender, J., Tollefsen, K.E., Mekenyan, O., Dimitrov, S., Bunke, D., Cousins, I., Posthuma, L., van den Brink, P.J., López de Alda, M., Barceló, D., Faust, M., Kortenkamp, A., Scrimshaw, M., Ignatova, S.N., Engelen, G., Massmann, G., Lemkine, G., Teodorovic, I., Walz, K.-H., Dulio, V., Jonker, M.T.O., Jäger, F., Chipman, K., Falciani, F., Liska, I., Rooke, D., Zhang, X., Hollert, H., Vrana, B., Hilscherova, K., Kramer, K., Neumann, S., Hammerbacher, R., Backhaus, T., Mack, J., Segner, H., Escher, B., De Aragão Umbuzeiro, G., (2015 ...
Arabinonucleosides. Accession Number. DBCAT000481. Description. Nucleosides containing arabinose as their sugar moiety. ...
0 (Adenine Nucleotides); 0 (Antimetabolites, Antineoplastic); 0 (Arabinonucleosides); 04079A1RDZ (Cytarabine); 143011-72-7 ( ...
Wilds, C. J. 2′-Deoxy-2′-fluoro-β-d-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. ...
... and arabinonucleosides. J Org Chem. 2000 Sep 22;65(19):5969-85. . . ...
... and arabinonucleosides. J Org Chem. 2000, 65(19), 5969-85. ...
Wilds, C. J., and Damha, M. J. 2′-Deoxy-2′-fluoro-β-D-arabinonucleosides and oligonucleotides (2′F- ANA): synthesis and ...
Arabinonucleosides / administration & dosage. Arabinonucleosides / adverse effects. Connective Tissue Growth Factor / blood. ... Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 0 / CTGF protein, human; 0 / Neoplasm Proteins; 0 / ...
Arabinonucleosides / therapeutic use. Drug Design. Neoplasms / drug therapy. *[MeSH-minor] Clinical Trials as Topic. Drug ... Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine ...
xiii) The sugar modification of modified nucleosides could consist of 2-deoxy-2-fluoro arabino nucleosides (2-F-ANAs) such ...
... generally includes ribonucleosides or arabinonucleosides in which the hydroxyl group at the 2 position of the pentose moiety ...
Gas-phase structures of protonated arabino nucleosides  Hamlow, L.A.; He, C.C.; Devereaux, Zachary J.; Roy, H.A.; Cunningham, ...
Arabinonucleosides/pharmacokinetics*. *Autoradiography. *Brain/metabolism. *Cladribine/pharmacokinetics*. *Clofarabine. * ...
Arabinonucleosides. Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims ...
Arabinonucleosides. 13. + +. 18. Aclarubicin. 12. + +. 19. Tretinoin. 12. + +. 20. Cyclin-Dependent Kinase Inhibitor p15. 12. + ...
Class Arabinonucleosides; Pyrimidine nucleosides * Mechanism of Action DNA synthesis inhibitors * Orphan Drug Status Orphan ...
Chemo-enzymatic synthesis of 3′-O,4′-C-methylene-linked α-l-arabinonucleosides ...
Adenine Nucleotides/pharmacology , Antimetabolites, Antineoplastic/pharmacology , Apoptosis/drug effects , Arabinonucleosides/ ...
Sugar-modified derivatives of cytostatic 6-(het)aryl-7-deazapurine nucleosides: 2′-C-methylribonucleosides, arabinonucleosides ...
Arabinonucleosides and Arabinonucleic Acids (ANA) [0011]Arabinonucleosides are stereoisomers of ribonucleosides, differing only ... 0013]DNA strands containing arabinonucleosides have also been a subject of a number of structural studies. In the crystal, DNA ... 0025]Also provided are oligonucleotides based on 2-deoxy-2-fluoro-β-D-arabinonucleosides (i.e., 2F-ANA oligomers) that bind ... fluoro-β-D-arabinonucleosides (i.e., 2F-ANA oligomers). ##STR00005## [0024]Prior to this invention, only the natural DNA ( ...
Enzynatic Synthesis of Purine Arabinonucleosides. EP 0002192 B1.. [10] Ling, F., Inoue, Y., Kimura, A., 1990. Purification and ...
Arabinonucleosides are epimers of ribonucleosides with the chiral switch being at the 2 position of the sugar residue. 2-F- ...
Studies directed toward the synthesis of 2-deoxy-2-substituted arabino nucleosides. Nucleic Acids Res. Symp. Ser. 1987, 18, ... Studies directed toward the synthesis of 2-deoxy-2-substituted-arabino nucleosides. 1. J. Heterocycl. Chem. 1985, 22, 1703- ... Studies directed toward the synthesis of 2-deoxy-2-substituted arabino nucleosides. 3. J. Org. Chem. 1985, 50, 3319-3322. ... Studies directed toward the synthesis of 2-deoxy-2-substituted arabino nucleosides. (4). Chem. Pharm. Bull. 1987, 35, 4494- ...
Arabinonucleosides*Cytarabine: 4912*BH-AC-AMP protocol: 1. *Polycyclic Compounds: 56*Steroids: 18537*Pregnanes: 3*Pregnadienes* ...
Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Arabinonucleosides / Prodrugs / Cricetulus / ... Full text: Available Index: WPRIM (Western Pacific) Main subject: Pharmacology / Arabinonucleosides / Prodrugs / Cricetulus / ... Animals , Antimetabolites, Antineoplastic , Pharmacology , Arabinonucleosides , Pharmacology , CHO Cells , Cricetinae , ...
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, therapeutic use, Arabinonucleosides, ...
Tyring SK, Lee P, Hill GT, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul; 89(7):1255-1264 ...
169 T. Théophanides, S. Hanessian, M. Manfait et M. Berjot, "Raman spectra of the Arabinonucleosides Ara-A and Ara-C", J. of ...
... or arabinonucleosides in which the hydroxyl group at the 2 position of the pentose moiety is substituted to produce a 2- ... also includes ribonucleosides or arabinonucleosides in which the 2-hydroxyl group is replaced with a lower alkyl group ...
Arabinonucleosides, Arsenicals, Clinical Trials, Phase III as Topic, Cost-Benefit Analysis, Cytarabine, Cytosine, Drug ...
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
  • Wilds, C. J. 2′-Deoxy-2′-fluoro-β- d -arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. (nature.com)